The Food and Drug Administration conditionally approved EnteroMedics Inc.'s (Nasdaq: ETRMD) neuroblocking Maestro RC System for treating obesity sending the stock price soaring 95 cents to $2.79.
Conditional Approval For EnteroMedics' Maestro RC System
August 02, 2010 at 13:38 PM EDT